Bayer (BAYN) Aktievy
Bayer Aktiengesellschaft är verksamt som ett life science-företag över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för BAYN från våra riskkontroller.
BAYN Community Fair Values
Create NarrativeSee what 267 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€40
FV
21.9% övervärderad intrinsisk rabatt182
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Bayer Aktiengesellschaft Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €48.74 |
| 52 veckors högsta | €53.92 |
| 52 veckors lägsta | €25.78 |
| Beta | 0.83 |
| 1 månads förändring | 0.58% |
| 3 månaders förändring | 24.24% |
| 1 års förändring | 73.51% |
| 3 års förändring | -2.89% |
| 5 års förändring | 1.44% |
| Förändring sedan börsintroduktionen | 257.87% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 05
BAYN: Glyphosate Ruling And Mixed Pipeline Outlook Will Shape Future Re Rating Potential
Analysts have lifted their Bayer fair value estimate from €31.26 to €46.00, reflecting higher price targets in recent research and greater confidence that glyphosate liabilities could remain capped within existing provisions following the recent Supreme Court ruling. Analyst Commentary Recent research on Bayer has become more constructive after the Supreme Court ruling on glyphosate, but not all commentary is positive.
Uppdatering av berättelse • Jul 22
BAYN: Glyphosate Litigation Clarity Will Drive Future Rerating Potential
Analysts have lifted their Bayer fair value estimate from €34.97 to €54.92. This reflects updated assumptions on revenue growth, profit margins, and future P/E multiples following recent research that highlights reduced glyphosate liability uncertainty and mixed, but generally more constructive, rating and price target revisions across the Street.
Uppdatering av berättelse • Jul 08
BAYN: Litigation Ruling And Settlement Progress Will Drive Future Re Rating
The analyst price target for Bayer has been revised higher from €60.00 to €63.81 as analysts factor in recent upgrades tied to progress on glyphosate litigation and mixed, but generally more constructive, Street research. Analyst Commentary Recent Street research on Bayer has turned more constructive, with several bullish analysts highlighting progress on glyphosate litigation and updated views on the company's pharmaceutical outlook.Recent updates
Uppdatering av berättelse • Aug 05
BAYN: Glyphosate Ruling And Mixed Pipeline Outlook Will Shape Future Re Rating Potential
Analysts have lifted their Bayer fair value estimate from €31.26 to €46.00, reflecting higher price targets in recent research and greater confidence that glyphosate liabilities could remain capped within existing provisions following the recent Supreme Court ruling. Analyst Commentary Recent research on Bayer has become more constructive after the Supreme Court ruling on glyphosate, but not all commentary is positive.Uppdatering av berättelse • Jul 22
BAYN: Glyphosate Litigation Clarity Will Drive Future Rerating Potential
Analysts have lifted their Bayer fair value estimate from €34.97 to €54.92. This reflects updated assumptions on revenue growth, profit margins, and future P/E multiples following recent research that highlights reduced glyphosate liability uncertainty and mixed, but generally more constructive, rating and price target revisions across the Street.Uppdatering av berättelse • Jul 08
BAYN: Litigation Ruling And Settlement Progress Will Drive Future Re Rating
The analyst price target for Bayer has been revised higher from €60.00 to €63.81 as analysts factor in recent upgrades tied to progress on glyphosate litigation and mixed, but generally more constructive, Street research. Analyst Commentary Recent Street research on Bayer has turned more constructive, with several bullish analysts highlighting progress on glyphosate litigation and updated views on the company's pharmaceutical outlook.Uppdatering av berättelse • Jun 24
BAYN: Litigation Progress And Key Approvals Will Drive Future Re Rating
Analysts nudged their average price target for Bayer slightly higher to about €40.50, citing updated views on litigation risks, the outlook for the asundexian pipeline, and recent recalibrations of valuation multiples such as forward P/E. Analyst Commentary Recent Street research around Bayer highlights a mixed but gradually improving tone, with several bullish analysts adjusting price targets and ratings as they reassess litigation exposure, the asundexian opportunity, and the conglomerate discount.Analysartikel • Jun 16
Bayer (XTRA:BAYN) Stock Could Be 9.2% Undervalued After FDA Approval Of AMBELVIST
Bayer (XTRA:BAYN) is back in focus after the U.S. FDA approved AMBELVIST, a macrocyclic gadolinium based contrast agent for contrast enhanced MRI in adults and pediatric patients, including term neonates. See our latest analysis for Bayer. Despite recent product and leadership announcements, Bayer’s 1 year total shareholder return of 32.05% contrasts with a 5 year total shareholder return that is down 24.26%, while its 90 day share price return is down 9.7%. This suggests longer term holders...Uppdatering av berättelse • Jun 06
BAYN: Litigation Resolution And Key Drug Approvals Will Drive Future Re Rating
Narrative Update on Bayer Analysts have lifted Bayer's blended price target to €40, with many highlighting higher published targets from firms such as DZ Bank, Deutsche Bank, Jefferies and UBS. They are still pointing to litigation outcomes and the asundexian data readout as key swing factors.Uppdatering av berättelse • May 22
BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential
Analysts have maintained the fair value estimate for Bayer at €60.00 and raised price targets in recent research, citing a series of upgrades, slightly higher assumptions for revenue growth and profit margins, as well as a modestly lower future P/E multiple following a broad reassessment of sector risks and company-specific legal developments. Analyst Commentary Recent research points to a clear shift toward more constructive views on Bayer, with several bullish analysts updating ratings and valuation frameworks in response to company specific developments and sector wide reassessments.Uppdatering av berättelse • May 05
BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential
Analysts have nudged the fair value estimate for Bayer higher to about €31.26 from €30.41, citing a series of recent upgrades and higher price targets that reflect updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Bayer has been mixed, with several firms updating ratings and price targets over the past few months.Uppdatering av berättelse • Apr 21
BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential
Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.Uppdatering av berättelse • Apr 06
BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside
Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.Uppdatering av berättelse • Mar 23
BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings
Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.Uppdatering av berättelse • Mar 09
BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings
Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.Uppdatering av berättelse • Feb 23
BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside
The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.Uppdatering av berättelse • Feb 09
BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside
Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.Analysartikel • Jan 27
The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More
Despite an already strong run, Bayer Aktiengesellschaft ( ETR:BAYN ) shares have been powering on, with a gain of 29...Uppdatering av berättelse • Jan 25
BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside
Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.Uppdatering av berättelse • Jan 09
BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares
Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.Uppdatering av berättelse • Dec 26
BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential
Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.Uppdatering av berättelse • Dec 11
BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares
Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.Analysartikel • Dec 03
Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce
Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders have had their patience rewarded with a 27% share price jump in the...Uppdatering av berättelse • Nov 27
BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares
Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.Analysartikel • Nov 14
Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a pretty great week for Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders, with its shares surging 13% to...Uppdatering av berättelse • Nov 13
BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum
Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.Aktieägarnas avkastning
| BAYN | DE Pharmaceuticals | DE Marknad | |
|---|---|---|---|
| 7D | -0.4% | -1.4% | -0.9% |
| 1Y | 73.5% | 40.3% | 2.2% |
Avkastning vs industri: BAYN översteg German Pharmaceuticals branschen som gav 40.3 % under det senaste året.
Avkastning vs Marknaden: BAYN översteg German marknaden som gav 2.2 % under det senaste året.
Prisvolatilitet
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stabil aktiekurs: BAYN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: BAYN s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1863 | 87,830 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft är ett världsomspännande life science-företag. Företaget är verksamt inom segmenten Pharmaceuticals, Consumer Health och Crop Science. Segmentet Pharmaceuticals tillhandahåller receptbelagda produkter främst inom kardiologi och kvinnohälsovård, specialiserade läkemedel inom områdena onkologi, hematologi och oftalmologi, utrustning för bilddiagnostik och kontrastmedel samt cell- och genterapi.
Bayer Aktiengesellschaft Sammanfattning av grunderna
| BAYN grundläggande statistik | |
|---|---|
| Börsvärde | €47.87b |
| Vinst(TTM) | -€1.74b |
| Intäkter(TTM) | €45.38b |
1.1x
P/S-förhållande-27.6x
P/E-förhållandeÄr BAYN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| BAYN resultaträkning (TTM) | |
|---|---|
| Intäkter | €45.38b |
| Kostnad för intäkter | €17.94b |
| Bruttovinst | €27.43b |
| Övriga kostnader | €29.17b |
| Intäkter | -€1.74b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Nov 03, 2026
| Vinst per aktie (EPS) | -1.77 |
| Bruttomarginal | 60.46% |
| Nettovinstmarginal | -3.83% |
| Skuld/egenkapitalförhållande | 124.8% |
Hur har BAYN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.2%
Aktuell utdelningsavkastning-6%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/18 06:12 |
| Aktiekurs vid dagens slut | 2026/08/18 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Bayer Aktiengesellschaft bevakas av 40 analytiker. 17 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Emily Field | Barclays |
| Charles Pitman | Barclays |